Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 5.99%
As of Thursday, July 23, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.99%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Commentary & Analysis
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Up 5.36%
As of Tuesday, July 21, Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 5.36%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Up 8.30%
As of Friday, July 17, Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 8.30%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 5.44%
As of Thursday, July 16, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 10.23%
As of Thursday, July 16, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 10.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $506.8 | $251.9 | 37% |
|
| Shares Out (Mil) | 24.7 | 50.8 | 34% |
|
| Institutional Ownership | 76.6% | 92.0% | 47% |
|
| Float (Mil) | 19.4 | 40.5 | 28% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 359 | 447 | 54% |
|
| Price Change (52-week) |
258.4% | 54.2% | 98% |
|
| Growth | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (36.0%) | (9.8%) | 11% |
|
| EPS (5yr) | 34.5% | 16.3% | 84 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.643) | ($2.433) | ($2.815) | |
| Month Ago EPS | ($0.643) | ($2.433) | ($2.815) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.770) | ($3.320) | ($2.477) | |
| Year/Year Chg | (32.5%) | (29.1%) | 3.6% | |
| Financials | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($87) | ($43) | 12% |
|
| EPS (TTM) | ($3.550) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($30) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $3 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $5 | 27% |
|
| Enterprise Value (Q1) (Mil) | $356 | $182 | 31% |
|
| Valuation | ARTV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.94 | 2.60 | 64% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (58.6%) | (49.7%) | 10% |
|
| ROE | (67.9%) | (55.4%) | 13% |
|
| Liabilities to Assets | 17.1% | 30.3% | 11% |
|
| F-Score | 2 | 3 | 7% |
|
Artiva Biotherapeutics, Inc. did not pass any screens on 7/30/2026.
